With regard to URGCP/URG4 expression in early-stage HCC patients (TNM stages I–II), analysis of patients with low URGCP/URG4 expression revealed a 5-year survival rate of 52.4%, whereas the survival rate decreased to 17.6% in the high-URGCP/URG4 group (P<0.001, Figure 2D). This evidence concerns the gene URGCP and hepatocellular carcinoma.